文献速递介入腹部US

使用组织碎化术进行非侵入性肝脏消融:在活体猪模型中的临床前安全性研究

Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model.
PubMed 文献 · Ultrasound Med Biol · 2017-03-17

本研究在22头活体猪中评估组织碎化术(一种非侵入性超声消融方法)用于肝脏消融的安全性,其中一半动物接受全身肝素化。所有动物均存活,组织碎化术在肝脏及治疗肝静脉周围产生边界清晰的病灶;非肝素化组中一头动物在15分钟血管治疗期间出现一过性pH升高及血压、心率和PCO2下降,治疗后很快恢复至基线。结果表明,组织碎化术无需全身肝素化即可安全用于肝脏,即使在大肝静脉区域也是如此,支持其未来用于肝癌治疗。

要点

  • 组织碎化术可在活体猪肝脏及肝静脉周围产生边界清晰的消融病灶,所有动物均存活。
  • 无需全身肝素化即可安全实施肝脏组织碎化术,包括大肝静脉区域。
  • 非肝素化组一头动物在15分钟血管治疗期间出现一过性生命体征和血气变化,治疗后恢复。

核心结论

  • 组织碎化术无需全身肝素化即可安全用于活体猪肝脏消融,即使在大肝静脉区域,支持其未来用于肝癌治疗。

研究设计与样本

  • 临床前在体猪模型安全性研究,共22头猪,一半接受全身肝素化;治疗由实时超声引导和监测,治疗后取组织做组织学分析。

关键影像表现/征象

  • 组织碎化术在所有动物的肝脏内及治疗肝静脉周围产生边界清晰的病灶。
  • 实时超声用于引导和监测所有治疗。
  • 非肝素化组一头动物在15分钟血管治疗期间出现一过性pH升高及血压、心率、PCO2下降,治疗后很快恢复至基线。
  • 所有动物均存活至治疗结束。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

This study investigates the safety profile for use of histotripsy, a non-invasive ultrasonic ablation method currently being developed for the treatment of liver cancer, for liver ablation in an in vivo porcine model. Histotripsy treatments were applied to the liver and hepatic veins of 22 porcine subjects, with half of the subjects receiving systemic heparinization. Vital signs (heart rate, blood pressure, temperature, electrocardiogram and SpO2) were monitored throughout the procedure and for 1 h post-treatment. Blood was drawn at six points during the experiment to analyze blood gases, liver function and free hemoglobin levels. All treatments were guided and monitored by real-time ultrasound imaging. After treatment, the tissue was harvested for histological analysis. Results indicated that histotripsy generated well-defined lesions inside the liver and around the treated hepatic veins of all subjects in both treatment groups. Vital signs and blood analysis revealed that animals responded well to histotripsy, with all animals surviving the treatment. One animal in the non-heparinized group had a transient increase in pH and decreases in blood pressure, heart rate and PCO2 during the 15-min vessel treatment, with these changes returning to baseline levels soon after the treatment. Overall, the results indicate that histotripsy can safely be performed on the liver without the need for systemic heparinization, even in regions containing large hepatic vessels, supporting its future use for the treatment of liver cancer.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Vlaisavljevich E, Owens G, Lundt J, et al. Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model. Ultrasound Med Biol. 2017. PMID: 28318889. doi:10.1016/j.ultrasmedbio.2017.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。